Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant viruses [3]

AIDS

Volumn 16, Issue 2, 2002, Pages 298-299

  Maggiolo, Franco ^a   Callegaro, Annapaola ^a   Gregis, Giampietro ^a   Quinzan, Giampaolo ^a   Ripamonti, Diego ^a   Arici, Claudio ^a   Goglio, Antonio ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; RITONAVIR; VIRUS RNA;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; RASH; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0037169242     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201250-00024     Document Type: Letter

References (8)

1. Multidrug rescue therapy (MDRT) for HIV-infected individuals with prior virologic failure to multiple regimens - Results from two cohorts
2. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort
3. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen
4. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
5. Effect of cessation of highly active antiretroviral therapy during discordant response: Implications for scheduled therapeutic inerruptions
6. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study
7. Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection
8. Rapid clearance of M184V mutation from proviral HIV DNA allows drug recycling in salvage therapy